Page 1830 - Hematology_ Basic Principles and Practice ( PDFDrive )

1632 Part X Transplantation

CONCLUSIONS Epperla N, Pasquini M, Pierce K, et al: Salvage haploidentical hematopoietic
cell transplantation for graft rejection following a prior haploidentical
HLA-haploidentical donors are a rapid and near universally available allograft. Bone Marrow Transplant 52:147, 2017.
source of HSCs for transplant into patients with poor-risk hemato- Ghosh N, Karmali R, Rocha V, et al: Reduced-intensity transplantation for
logic malignancies. HLA mismatch between donor and recipient lymphomas using haploidentical related donors versus HLA-matched
stimulates not only alloreactive T cells but also NK and B cells, which sibling donors: a Center for International Blood and Marrow Transplant
generates unique biologic and clinical considerations. The major Research analysis. J Clin Oncol 34:3141, 2016.
drawback of HLA-haploidentical SCT is intense bidirectional allore- Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al: Reduced-intensity
activity resulting in higher incidences of graft failure, GVHD, and transplantation for lymphomas using haploidentical related donors vs
NRM. Three modern approaches to haploSCT have mitigated these HLA-matched unrelated donors. Blood 127(7):938–947, 2016.
complications substantially: (1) megadose T cell–depleted SCTs; (2) Leffell MS, Jones RJ, Gladstone DE: Donor HLA-specific Abs: to BMT or
the GIAC protocol involving administration of ATG, filgrastim- not to BMT? Bone Marrow Transplant 50:751, 2015.
mobilized marrow plus PBSCs, and intensive posttransplant immu- Leventhal JR, Elliott MJ, Yolcu ES, et al: Immune reconstitution/
nosuppression; and (3) high-dose, posttransplant cyclophosphamide immunocompetence in recipients of kidney plus hematopoietic stem/
as part of GVHD prophylaxis. Outcomes of haploSCT for hemato- facilitating cell transplants. Transplantation 99(2):288–298, 2015.
logic malignancies using these strategies now approach those seen McCurdy SR, Kanakry JA, Showel MM, et al: Risk-stratified outcomes of
after HLA-matched SCT. Prospective randomized trials comparing nonmyeloablative, HLA-haploidentical BMT with high-dose posttrans-
different graft sources will be needed to determine the donor priority plantation cyclophosphamide. Blood 125:3024, 2015.
for patients referred for allogeneic SCT. Priorities for future research O’Donnell PV, Eapen M, Horowitz MM, et al: Comparable outcomes with
include improving immune reconstitution and preventing or treating marrow or peripheral blood as stem cell sources for hematopoietic cell
relapsed malignancy. transplantation from haploidentical donors after non-ablative condition-
ing: a matched-pair analysis. Bone Marrow Transplant 51:2016, 1599.
O’Donnell P, Raj K, Pagliuca A: High fever occurring 4 to 5 days post-
SUGGESTED READINGS transplant of haploidentical bone marrow or peripheral blood stem cells
after reduced-intensity conditioning associated with the use of post-
Abboud R, Keller J, Slade M, et al: Severe cytokine-release syndrome after transplant cyclophosphamide as prophylaxis for graft-versus-host disease.
T cell-replete peripheral blood haploidentical donor transplantation is Biol Blood Marrow Transplant 21(1):197–198, 2015.
associated with poor survival and anti-IL-6 therapy is safe and well toler- Or-Geva N, Reisner Y: The evolution of T-cell depletion in haploidentical
ated. Biol Blood Marrow Transplant 22:2016, 1851. stem-cell transplantation. Br J Haematol 172(5):667–684, 2016.
Aboul Nour H, Patil N, Chewning JH, et al: Safety of repeated un-manipulated Rimondo A, Crocchiolo R, El-Cheikh J, et al: The calcineurin inhibitor and
peripheral blood stem cell haploidentical transplant for graft failure. Bone the intensity of the conditioning regimen may affect the occurrence of
Marrow Transplant 52:157, 2017. polyomavirus-associated hemorrhagic cystitis after haploidentical hemato-
Al-Homsi AS, Cole K, Bogema M, et al: Short course of post-transplantation poietic stem cell transplantation with post-transplant cyclophosphamide.
cyclophosphamide and bortezomib for graft-versus-host disease preven- Bone Marrow Transplant 52:135, 2017.
tion after allogeneic peripheral blood stem cell transplantation is feasible Ringdén O, Labopin M, Ciceri F, et al: Is there a stronger graft-versus-leu-
and yields favorable results: a phase I study. Biol Blood Marrow Transplant kemia effect using HLA-haploidentical donors than with HLA-identical
21:1315, 2015. siblings? Leukemia 30:447, 2016.
Arcese W, Picardi A, Santarone S, et al: Haploidentical, G-CSF-primed, Ruggeri A, Labopin M, Sanz G, et al: Comparison of outcomes after unrelated
unmanipulated bone marrow transplantation for patients with high-risk cord blood and unmanipulated haploidentical stem cell transplantation in
hematological malignancies: an update. Bone Marrow Transplant 50(Suppl adults with acute leukemia. Leukemia 29(9):1891–1900, 2015.
2):S24, 2015. Ruggeri A, Roth-Guepin G, Battipaglia G, et al: Incidence and risk factors
Bramanti S, Nocco A, Mauro E, et al: Desensitization with plasma exchange for hemorrhagic cystitis in unmanipulated haploidentical transplant
in a patient with human leukocyte antigen donor-specific antibod- recipients. Transpl Infect Dis 17:822, 2015.
ies before T-cell–replete haploidentical transplantation. Transfusion Solomon SR, Sizemore CA, Sanacore M, et al: Total body irradiation-based
56(5):1096–1100, 2016. myeloablative haploidentical stem cell transplantation is a safe and effec-
Chen H, Liu KY, Xu LP, et al: Haploidentical hematopoietic stem cell tive alternative to unrelated donor transplantation in patients without
transplantation without in vitro T cell depletion for the treatment of matched sibling donors. Biol Blood Marrow Transplant 21:1299, 2015.
Philadelphia chromosome–positive acute lymphoblastic leukemia. Biol Stokes J, Hoffman EA, Zeng Y, et al: Post-transplant bendamustine reduces
Blood Marrow Transplant 21:1110, 2015. GvHD while preserving GvL in experimental haploidentical bone marrow
Ciurea SO, Thall PF, Milton DR, et al: Complement-binding donor-specific transplantation. Br J Haematol 174(1):102–116, 2016.
anti-HLA antibodies and risk of primary graft failure in hematopoietic Tang BL, Zhu XY, Zheng CC, et al: Successful early unmanipulated haploi-
stem cell transplantation. Biol Blood Marrow Transplant 21(8):1392–1398, dentical transplantation with reduced-intensity conditioning for primary
2015. graft failure after cord blood transplantation in hematologic malignancy
Ciurea SO, Zhang MJ, Bacigalupo AA, et al: Haploidentical transplant with patients. Bone Marrow Transplant 50(2):248–252, 2015.
posttransplant cyclophosphamide vs matched unrelated donor transplant Wang Y, Liu QF, Xu LP, et al: Haploidentical vs identical-sibling trans-
for acute myeloid leukemia. Blood 126(8):1033–1040, 2015. plant for AML in remission: a multicenter, prospective study. Blood
Crocchiolo R, Bramanti S, Vai A, et al: Infections after T-replete haploidenti- 125(25):3956–3962, 2015.
cal transplantation and high-dose cyclophosphamide as graft-versus-host
disease prophylaxis. Transpl Infect Dis 17:242, 2015.
Crucitti L, Crocchiolo R, Toffalori C, et al: Incidence, risk factors and clinical REFERENCES
outcome of leukemia relapses with loss of the mismatched HLA after
partially incompatible hematopoietic stem cell transplantation. Leukemia For the complete list of references, log on to www.expertconsult.com.
29(5):1143–1152, 2015.